These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 37145008)
1. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort. Akyildiz A; Guven DC; Yildirim HC; Ismayilov R; Yilmaz F; Tatar OD; Chalabiyev E; Kus F; Yalcin S; Aksoy S Medicine (Baltimore); 2023 May; 102(18):e33677. PubMed ID: 37145008 [TBL] [Abstract][Full Text] [Related]
2. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Kınıkoğlu O; Odabas H; Altıntaş YE; Yıldız A; Çakan B; Akdağ G; Yıldırım S; Bal H; Kaya T; Tünbekici S; Işık D; Başoğlu T; Yıldırım ME; Turan N Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929568 [No Abstract] [Full Text] [Related]
3. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L; Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Noda-Narita S; Shimomura A; Kawachi A; Sumiyoshi-Okuma H; Sudo K; Shimoi T; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Tamura K Breast Cancer; 2019 Jul; 26(4):492-498. PubMed ID: 30737616 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis. Ciapponi A; Bardach A; Colaci C; Rodríguez Cairoli F; Argento F; Korbenfeld E; García Martí S Rev Peru Med Exp Salud Publica; 2024 May; 41(1):7-18. PubMed ID: 38808848 [TBL] [Abstract][Full Text] [Related]
7. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091 [TBL] [Abstract][Full Text] [Related]
9. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686 [TBL] [Abstract][Full Text] [Related]
10. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616 [TBL] [Abstract][Full Text] [Related]
12. Trastuzumab emtansine for HER2-positive advanced breast cancer. Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K; N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis. Yeh Y; Chen C; Ko Y J Cancer Res Ther; 2022; 18(4):1061-1072. PubMed ID: 36149162 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort. Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120 [TBL] [Abstract][Full Text] [Related]
17. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. Daniels B; Kiely BE; Tang M; Houssami N; Lord SJ; Pearson SA Breast; 2021 Aug; 58():106-112. PubMed ID: 33992964 [TBL] [Abstract][Full Text] [Related]
18. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Baselga J; Lewis Phillips GD; Verma S; Ro J; Huober J; Guardino AE; Samant MK; Olsen S; de Haas SL; Pegram MD Clin Cancer Res; 2016 Aug; 22(15):3755-63. PubMed ID: 26920887 [TBL] [Abstract][Full Text] [Related]
19. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]